Q/C Technologies, Inc. (QCLS) Stock

Q/C Technologies, Inc. (QCLS) is a Healthcare stock trading at $1.92 (as of 2026-09-02), with a market capitalization of $15.68M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Q/C Technologies, Inc. (QCLS) works on quantum-class photonic computing and blockchain-related infrastructure. The company holds exclusive worldwide rights to LightSolver’s light processing unit, which uses laser-based computing for cryptocurrency applications.

Understand Q/C Technologies, Inc.: how it makes money

Q/C Technologies holds exclusive global rights to a light-speed laser processing unit (LPU) aimed at cryptocurrency vertical applications, though the company has generated no revenue to date. The entire investment case rests on whether this single photonic hardware product ever reaches paying customers.

Q/C Technologies has no revenue, no customers, and no demonstrated profit model; its entire future depends on one unproven technology (the LPU) reaching commercial deployment in the crypto sector.

Business quality (Unprofitable): Unprofitable with no revenue and an operating margin of -14543%. The company is in a pre-commercial development stage with no visible path to breakeven.

Bear case

  • No revenue, steep cash burn: Operating margin sits at -14543% against effectively zero revenue, meaning the company is consuming operating cash with no commercial offset to reduce the burn. Until the LPU generates its first dollar of income, this gap will only widen as development costs accrete.
Valuation — source: SEC EDGAR (first-party)
Price$1.92
Market Cap$15.68M
Price / Book0.97
FCF Yield-69.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.58M
Net Margin-246.6%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPrivate Advisor Group, LLC ($1.33M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua N. Silverman
Employees6
CountryUS
IPO Date2014-01-23

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • VolitionRx Limited (VNRX)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Biomerica, Inc. (BMRA)
  • OneMedNet Corporation (ONMD)
  • iSpecimen Inc. (ISPC)
  • 20/20 Biolabs, Inc. Common Stock (AIDX)
  • BNB Plus Corp. (BNBX)
  • Absci Corporation (ABSI)
QCLS earnings history · QCLS institutional & insider holders · QCLS KPIs & operating metrics · QCLS financials · QCLS investor presentations & press releases · QCLS SEC filings · QCLS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.